Drug Persistence/Adherence in Patients Treated With Dabigatran or VKA for Stroke Prevention in Non Valvular Atrial Fibrillation (SPAF)

Boehringer Ingelheim1,506 enrolled

Overview

1600 AF patients receiving Pradaxa or VKA for stroke prevention will be followed up for 12 months in quarterly visits. Prescriptions, adverse events and (if applicable) reasons for definitive treatment discontinuation will be collected. At 6 months, patient adherence will be assessed, using the Morisky Score.

Study Type

OBSERVATIONAL

Enrollment

1,506

Conditions

Atrial Fibrillation

Interventions

Dabigatran etexilateDRUG

150 mg or 110 mg capsules twice daily

Vitamin K antagonistsDRUG

International Normalized Ratio (INR) 2-3

Eligibility

Sex: ALLMin age: 18 Years

Medical Language ↔ Plain English

Inclusion criteria: * Newly prescribed treatment with Pradaxa® (dabigatran etexilate)/VKA in the indication "Stroke prevention in non-valvular atrial fibrillation" (AF) respecting the indication and contraindications as described in the respective Summary of Product Characteristics for Pradaxa® 110 mg or 150 mg hard capsules or the appropriate VKA (patients are eligible for both Pradaxa® and VKA therapy). * Treatment with dabigatran etexilate or VKA is given in accordance with the respective Summaries of Product Characteristics. The routine diagnostic procedures and treatment that would be undertaken irrespective of the study are unaffected. * Only patients who are eligible both for therapy with Pradaxa® and for therapy with VKA in accordance with the respective Summaries of Product Characteristics will be documented (patients eligible for VKA and Pradaxa®) * Patients must have signed the patient consent form prior to inclusion in the Non-Interventional Study (NIS). Exclusion criteria: * Patients with the general and special contraindications mentioned in the packaging leaflet or Summary of Product Characteristics must not be included. * Patients participating at the same time or within the last 30 days in another Non-Interventional Study (NIS) or an interventional clinical trial must not be included. * Patients treated with anticoagulants for a condition other than non-valvular atrial fibrillation must not be included. * Pradaxa® and VKA should not be used during pregnancy and lactation. Pregnant or breastfeeding women must therefore not be included in the NIS.

Locations (1)

Unnamed facility

Multiple Locations, Germany

Outcomes

Primary Outcomes

Percentage of Patients Treated With Anticoagulation Initially Started at the 12 Month

Percentage of patients treated with the initially allocated anticoagulant at the 12-month visit, defined as Kaplan Meier estimate at 12 months for persistence, stratified for dabigatran etexilate and VKA.Persistence is defined as the time between initiation and permanent discontinuation of therapy. The initiation date is the documented start of treatment (at visit 1), and the date of permanent discontinuation is the documented permanent discontinuation of dabigatran etexilate or VKA therapy.

Time frame: 12 month (Visit 5)

Secondary Outcomes

Percentage of Patients With Low, Medium or High Adherence at the Timepoint of 6 Months-visit.

Percentage of patients with low, medium or high adherence at the 6-month visit, stratified for dabigatran etexilate and VKA; categorisation is done on the basis of the Morisky questionnaire (high, medium and low adherence with a Morisky score of 0, 1 to 2, and \> 2, respectively).

Time frame: 6 month (visit 3)

Number of Patients With the Reason for Definitive Treatment Discontinuation

Number of patients with the reason for definitive treatment discontinuation

Time frame: Visit 2, 3, 4 and 5 (after approx. 3, 6, 9 and 12 months of treatment)

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.